Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Comment by mining4dollarson May 09, 2013 10:03pm

187 Views

Post# 21361169

RE: RE: RE: RE: RE: RE: RE: I hope......

No mention of what exactly would be in there, though I did certainly get the impression it would be more substantive than their initial update.

I am definitely hoping for some sort of efficacy...any indications would be great ie. which control group is seeing better results; how phase 2 results are comparing against initial phase 1 etc.. anything would be HIGHLY welcomed in the marketplace..

either way, Interim results will be out shortly... A huge catalyst nonetheless!

Bullboard Posts

Canadian artificial intelligence ETFs